ACCD — Accolade Share Price
Last Trade - 00:00- $2.76bn
- $2.62bn
- $193.99m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 28th Feb | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 76.83 | 94.81 | 132.51 | 170.36 | 303.43 | 395.13 | 30.4% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Accolade Inc. is a provider of personalized, technology-enabled solutions that helps people to understand, navigate, and utilize the healthcare system and their workplace benefits. The Company’s customers are primarily employers that deploy Accolade in order to provide employees and their families members a single place to turn for their health, healthcare, and benefits needs. Its platform combines open, cloud-based intelligent technology with multimodal support from a team of Accolade Health Assistants and clinicians (including nurses, physician medical directors, and behavioral health specialists). It leverages its integrated capabilities, connectivity with providers and the broader healthcare ecosystem, and longitudinal data to engage across the entire member population. The Company’s offerings are: Accolade Total Benefits, Accolade Total Care, Accolade Total Health and Benefits and Accolade Boost.
Directors
- Rajeev Singh CHM (51)
- Robert Cavanaugh (52)
- Stephen Barnes (49)
- Richard Eskew
- Todd Clardy
- Matt Eurey
- Beverly Gibson
- Phong Nguyen
- Britt Provost
- David Wyatt
- Mike McGee
- Sarah Martino
- Bill Morrison
- Harish Naidu
- Tina Gilbert
- Michael Hilton (56)
- Shantanu Nundy
- Carolyn Young
- Peter Klein LED (58)
- Jeffrey Brodsky (56)
- Elizabeth Nabel (69)
- Jeffrey Jordan (62)
- Dawn Lepore (66)
- James Madden (59)
- Thomas Neff (82)
- Patricia Wadors (55)
- Michael Yang (49)
- Last Annual
- February 28th, 2021
- Last Interim
- May 31st, 2021
- Incorporated
- January 23rd, 2007
- Public Since
- January 1st, 1970
- No. of Shareholders
- 128
- No. of Employees
- 1,720
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 66,073,740
- Address
- 660 West Germantown Pike, Suite 500, PLYMOUTH MEETING, 19462
- Web
- https://www.accolade.com
- Phone
- +1 2069268100
- Auditors
- KPMG LLP
Latest News for ACCD
Upcoming events for ACCD
Q2 2022 Accolade Inc Earnings Release
Q2 2022 Accolade Inc Earnings Release
Q3 2022 Accolade Inc Earnings Release
Q3 2022 Accolade Inc Earnings Release
Similar to ACCD
ACADIA HEALTHCARE ORD
NASDAQ Global Select Market
AVEANNA HEALTHCARE HOLDINGS ORD
NASDAQ Global Select Market
CORVEL ORD
NASDAQ Global Select Market
INNOVAGE HOLDING ORD
NASDAQ Global Select Market
LIFESTANCE HEALTH ORD
NASDAQ Global Select Market
FAQ
As of Today at 19:56 UTC, shares in Accolade are trading at $41.80. This share price information is delayed by 15 minutes.
Shares in Accolade last closed at $41.80 and the price had moved by +10.29% over the past 365 days. In terms of relative price strength the Accolade share price has underperformed the S&P500 Index by -16.33% over the past year.
The overall consensus recommendation for Accolade is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Accolade does not currently pay a dividend.
Accolade does not currently pay a dividend.
Accolade does not currently pay a dividend.
To buy shares in Accolade you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $41.80, shares in Accolade had a market capitalisation of $2.76bn.
Here are the trading details for Accolade:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ACCD
Shares are classified based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Accolade does not currently have a style classification.
The analyst consensus target price for shares in Accolade is $63.00. That is 50.72% above the last closing price of $41.80.
Analysts covering Accolade currently have a consensus Earnings Per Share (EPS) forecast of -$2.02 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Accolade. Over the past six months, its share price has underperformed the S&P500 Index by -29.98%.
As of the last closing price of $41.80, shares in Accolade were trading -13.06% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Accolade.
Accolade's management team is headed by:
- Rajeev Singh - CHM
- Robert Cavanaugh -
- Stephen Barnes -
- Richard Eskew -
- Todd Clardy -
- Matt Eurey -
- Beverly Gibson -
- Phong Nguyen -
- Britt Provost -
- David Wyatt -
- Mike McGee -
- Sarah Martino -
- Bill Morrison -
- Harish Naidu -
- Tina Gilbert -
- Michael Hilton -
- Shantanu Nundy -
- Carolyn Young -
- Peter Klein - LED
- Jeffrey Brodsky -
- Elizabeth Nabel -
- Jeffrey Jordan -
- Dawn Lepore -
- James Madden -
- Thomas Neff -
- Patricia Wadors -
- Michael Yang -
We do not have data on Accolade's shareholders